Neuraxis Inc (NRXS) Q4 2025 Earnings Call Transcript

Why It Matters

The results validate Neurocrine’s rare‑disease commercial engine and fund a pipeline that could deliver two additional best‑in‑class neuropsychiatric medicines, reinforcing long‑term growth prospects.

Key Takeaways

• Total sales $2.8B, 22% YoY growth.
• INGREZZA revenue $2.5B, 9% increase.
• CRENESSITY $300M, 10% CAH market share.
• Cash balance $2.5B, $700M increase.
• Phase III osavampator, direclidine data due 2027.

Pulse Analysis

Neurocrine’s Q4 performance underscores the durability of its VMAT2 inhibitor franchise. INGREZZA, the first approved treatment for tardive dyskinesia, continues to expand its patient base through aggressive formulary negotiations and a refreshed sales force, delivering double‑digit volume growth despite modest pricing concessions. The drug’s near‑record prescription numbers reflect a broader trend toward specialty neurology therapies, positioning Neurocrine to capture additional share of the estimated 9‑out‑of‑10 untreated TD or HD chorea patients. This momentum not only fuels revenue but also strengthens the company’s leverage in future pricing discussions.

The launch of CRENESSITY marks a rare‑disease breakthrough, offering the first FDA‑approved therapy for classic congenital adrenal hyperplasia in seven decades. By securing 10% penetration in its target population within a year, the product demonstrates strong physician adoption, especially among endocrinologists, while the company’s plan to extend outreach to primary‑care and OB‑GYN providers could unlock further growth. High two‑year persistence rates and an absence of new safety signals reinforce its value proposition, and the ongoing expansion of a dedicated sales team, bolstered by AI‑driven targeting, aims to deepen market saturation without sacrificing profitability.

Looking ahead, Neurocrine’s robust cash position—now $2.5 billion—provides ample runway for continued R&D investment. Mid‑30% of sales are earmarked for research, supporting Phase III trials of osavampator for major depressive disorder and direclidine for schizophrenia, both slated to report data in 2027. Coupled with a disciplined SG&A spend at roughly 40% of sales, the company is poised to sustain its 30% non‑GAAP operating margin while expanding its pipeline. Investors view this blend of cash generation, disciplined capital allocation, and a diversified late‑stage portfolio as a compelling catalyst for long‑term shareholder value.